Based in Bensheim, Germany, Sanner GmbH was founded in 1894 and is now in its fourth generation as a family-owned enterprise. Sanner develops and produces high-quality plastic packaging and components for pharmaceutical, medtech, diagnostics and healthcare products. The world’s leading manufacturer of desiccant closures and effervescent packaging solutions, Sanner produces four billion plastic parts each year for standard and customized packaging solutions. With almost 600 employees in Germany, China, France, Hungary, the U.S., India and Indonesia, the company generated annual sales of approx. 98 million euros in 2020.
In 2020, Sanner was able to report record sales of approx. 98 million euros – an increase of almost 15 percent. Although this significant growth is partly due to the Corona-related demand, the manufacturer of medtech products and pharmaceutical packaging solutions anticipates steady growth in the coming years. This year, Sanner even expects to hit the 100-million-euro mark.
Sanner is all set for growth: following an above-average sales success in 2020, the forecasts for the coming years are also positive: “Especially our developments in the areas of intelligent medtech products and customized solutions promise further revenue. In fact, we expect to easily hit the 100-million-euro mark in 2021,” says Managing Director Dr. Johannis Willem van Vliet. “By expanding our sites in Germany and China, we are also creating further capacities for development and production. All in all, this gives us a very positive outlook for the future.”
Expansion despite of Covid-19
The above-average increase in sales can mainly be attributed to the strong demand in China, closely followed by Europe and the U.S. Due to the Corona pandemic, Sanner classics such as the DASG 1 desiccant closure, which is used worldwide for the packaging of vitamin C effervescent tablets, were in particular demand – sometimes even to the extent of a 30 percent increase globally. “We expect this demand to level off again in Europe and the U.S. as the pandemic recedes,” says Claudia Tonhäuser, Chief Financial Officer (CFO) at Sanner. “However, we are confident that we will compensate for this drop in sales with new products and concepts.”
Despite the pandemic, Sanner has taken decisive steps toward the future at several locations: for example, all requirements for the construction of the second plant in China have been met. The groundbreaking ceremony is scheduled to take place before fall 2021. Changes are also on the horizon at the company’s headquarters: this year, planning will begin for the new site in the Stubenwald II industrial park in Bensheim. The move is scheduled to take place in the course of 2024. The new site will provide additional research and development capacities for customized solutions and medical technology products – complemented by state-of-the-art production equipment, including electronics and cleanroom production. “This way, we are strengthening our site strategy in Germany and are further expanding it with ecological aspects,” says van Vliet.
Focus on growth and patient safety
In addition to the economic efforts, the company’s focus is on the human factor: “If we manage to improve patient safety, therapy adherence, and sustainability – and thus the quality of life for hundreds of thousands of people – with our solutions step by step, we have achieved our goal,” says van Vliet. In the coming years, Sanner will not only focus on new primary packaging solutions for medical cannabis or the Sanner BioBase® portfolio, but above all on the development of intelligent medtech solutions.
For further information please visit: www.sanner-group.com
